Transthyretin Amyloid Cardiomyopathy Attr Cm clinical trials

Explore recruiting transthyretin amyloid cardiomyopathy attr cm clinical trials.

Recruiting transthyretin amyloid cardiomyopathy attr cm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Transthyretin Amyloid Cardiomyopathy Attr Cm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Ireland, Belgium, Denmark, Spain, Portugal, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).

Portugal, Netherlands, Germany, Spain, Czechia, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (ATTR CM)

Italy, Czechia, Netherlands, France, Spain, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).

Germany, France, Belgium, Italy, Denmark, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Spain, Netherlands, Poland, Italy, Belgium, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Transthyretin Amyloid Cardiomyopathy Attr Cm trials by city

Transthyretin Amyloid Cardiomyopathy Attr Cm in Toronto Transthyretin Amyloid Cardiomyopathy Attr Cm in Vancouver Transthyretin Amyloid Cardiomyopathy Attr Cm in Montreal Transthyretin Amyloid Cardiomyopathy Attr Cm in Calgary Transthyretin Amyloid Cardiomyopathy Attr Cm in Edmonton Transthyretin Amyloid Cardiomyopathy Attr Cm in Ottawa Transthyretin Amyloid Cardiomyopathy Attr Cm in Winnipeg Transthyretin Amyloid Cardiomyopathy Attr Cm in Quebec City Transthyretin Amyloid Cardiomyopathy Attr Cm in Hamilton Transthyretin Amyloid Cardiomyopathy Attr Cm in Kitchener Transthyretin Amyloid Cardiomyopathy Attr Cm in London Transthyretin Amyloid Cardiomyopathy Attr Cm in Halifax Transthyretin Amyloid Cardiomyopathy Attr Cm in New York Transthyretin Amyloid Cardiomyopathy Attr Cm in Los Angeles Transthyretin Amyloid Cardiomyopathy Attr Cm in Chicago Transthyretin Amyloid Cardiomyopathy Attr Cm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease